ReviewJournal of epilepsy research2014
Old versus New: Why Do We Need New Antiepileptic Drugs?
Review in Journal of epilepsy research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Treatment Guidelines for Rare, Early-Onset, Treatment-Resistant Epileptic Conditions: A Literature Review on Dravet Syndrome, Lennox-Gastaut Syndrome and CDKL5 Deficiency Disorder.Frontiers in neurology · 2021Pooled it
- Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations.PharmacoEconomics · 2019Pooled it
- Effect of Folic Acid Supplementation on Seizure Control in Epileptic Children Receiving Long Term Antiepileptic Therapy.Indian journal of pediatrics · 2018Trial
- Natural Products in Epilepsy Treatment: From Traditional Medicine Towards Computational Drug Discovery.Current issues in molecular biology · 2026Review
- Ten-year projection of adult epilepsy burden in Australia.Epilepsia · 2025Article
- Brivaracetam, Another Useful Antiseizure Medication.Journal of epilepsy research · 2025Article
- Practices in the prescription of antiseizure medications: is it time to change?Arquivos de neuro-psiquiatria · 2024Article
- Pathophysiology to Risk Factor and Therapeutics to Treatment Strategies on Epilepsy.Brain sciences · 2024Review
- Anti-seizure Medications: Challenges and Opportunities.CNS & neurological disorders drug targets · 2024Review
- Acute and Sub-chronic Anticonvulsant Effects of Edaravone on Seizure Induced by Pentylenetetrazole or Electroshock in Mice, Nitric Oxide Involvement.Iranian journal of medical sciences · 2023Article
- Evaluation of Pharmacology and Pathophysiology Knowledge of Epilepsy among Senior Pharmacy Students: A Single Center Experience.Medicina (Kaunas, Lithuania) · 2023Article
- Pharmacoeconomics Aspects of Antiepileptic Drugs in Pediatric Patients with Epilepsy.International journal of environmental research and public health · 2022Article
- Osteogenic Effect of Pregabalin in Human Primary Mesenchymal Stem Cells, Osteoblasts, and Osteosarcoma Cells.Life (Basel, Switzerland) · 2022Article
- Research priorities for idiopathic epilepsy in dogs: Viewpoints of owners, general practice veterinarians, and neurology specialists.Journal of veterinary internal medicine · 2021Article
- The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies.Frontiers in neurology · 2021Review
- NMDA Receptor Mediates the Anticonvulsant Effect of Hydroalcoholic Extract ofEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Experimental Therapeutic Strategies in Epilepsies Using Anti-Seizure Medications.Journal of experimental pharmacology · 2021Review
- Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis.PharmacoEconomics · 2020Article
- Antiepileptic drug effects on subjective and objective cognition.Epilepsy & behavior : E&B · 2020Article
- The Risk Of Seizure-Related Hospitalization Among Older Adults On Levetiracetam Monotherapy: A Retrospective Comparative Cohort Study.Neuropsychiatric disease and treatment · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achieving complete seizure remission without adverse events is the goal of epilepsy treatment. Recently, many new antiepileptic drugs (AEDs) have been developed. Even though the efficacy of new AEDs is not stronger than that of old AEDs, there are advantages in using new AEDs. They have unique or different mechanisms of action that enable the creation of possible synergistic combinations. They usually exhibit fewer or no pharmacokinetic drug interactions. Furthermore, the response to AEDs varies individually. A similar efficacy does not imply a similar response from all patients. Many new AEDs have fewer adverse events, including induction of congenital malformations. Other concerns about the long-term effects of established AEDs, such as bone health and development of atherosclerosis, may be alleviated by the use of new AEDs. New AEDs are needed to achieve better care of patients with epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.